Citations (45)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Jerry Colca. (2020) NASH (nonalcoholic steatohepatitis), diabetes, and macrovascular disease: multiple chronic conditions and a potential treatment at the metabolic root. Expert Opinion on Investigational Drugs 29:2, pages 191-196.
Read now
Read now
Jerry R. Colca, William G McDonald & Wade J. Adams. (2018) MSDC-0602K, a metabolic modulator directed at the core pathology of non-alcoholic steatohepatitis. Expert Opinion on Investigational Drugs 27:7, pages 631-636.
Read now
Read now
Melissa A. Davidson, Donald R. Mattison, Laurent Azoulay & Daniel Krewski. (2018) Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future. Critical Reviews in Toxicology 48:1, pages 52-108.
Read now
Read now
Jerry R. Colca. (2015) The TZD insulin sensitizer clue provides a new route into diabetes drug discovery. Expert Opinion on Drug Discovery 10:12, pages 1259-1270.
Read now
Read now
N. Esser, N. Paquot & A. J. Scheen. (2015) Inflammatory markers and cardiometabolic diseases. Acta Clinica Belgica 70:3, pages 193-199.
Read now
Read now
Hardik Joshi, Tanushree Pal & CS Ramaa. (2014) A new dawn for the use of thiazolidinediones in cancer therapy. Expert Opinion on Investigational Drugs 23:4, pages 501-510.
Read now
Read now
Articles from other publishers (39)
Sotiria Tavoulari, Maximilian Sichrovsky & Edmund R. S. Kunji. (2023) Fifty years of the mitochondrial pyruvate carrier: New insights into its structure, function, and inhibition. Acta Physiologica.
Crossref
Crossref
Jerry R. Colca & Brian N. Finck. (2022) Metabolic Mechanisms Connecting Alzheimer’s and Parkinson’s Diseases: Potential Avenues for Novel Therapeutic Approaches. Frontiers in Molecular Biosciences 9.
Crossref
Crossref
Sotiria Tavoulari, Tom J.J. Schirris, Vasiliki Mavridou, Chancievan Thangaratnarajah, Martin S. King, Daniel T.D. Jones, Shujing Ding, Ian M. Fearnley & Edmund R.S. Kunji. (2022) Key features of inhibitor binding to the human mitochondrial pyruvate carrier hetero-dimer. Molecular Metabolism 60, pages 101469.
Crossref
Crossref
Jerry R. Colca & Philipp E. Scherer. (2022) The metabolic syndrome, thiazolidinediones, and implications for intersection of chronic and inflammatory disease. Molecular Metabolism 55, pages 101409.
Crossref
Crossref
Renée N. O. Silva, Ricardo P. Llanos, Rosangela A. S. Eichler, Thiago B. Oliveira, Fábio C. Gozzo, William T. Festuccia & Emer S. Ferro. (2021) New Intracellular Peptide Derived from Hemoglobin Alpha Chain Induces Glucose Uptake and Reduces Blood Glycemia. Pharmaceutics 13:12, pages 2175.
Crossref
Crossref
Paulina Escandon, Brenda Vasini, Amy E. Whelchel, Sarah E. Nicholas, H. Greg Matlock, Jian-Xing Ma & Dimitrios Karamichos. (2021) The role of peroxisome proliferator-activated receptors in healthy and diseased eyes. Experimental Eye Research 208, pages 108617.
Crossref
Crossref
Yuxin Zhou, Yongjian Guo, Yejin Zhu, Yuening Sun, Wei Li, Zhiyu Li & Libin Wei. (2021) Dual PPARγ/ɑ agonist oroxyloside suppresses cell cycle progression by glycolipid metabolism switch-mediated increase of reactive oxygen species levels. Free Radical Biology and Medicine 167, pages 205-217.
Crossref
Crossref
Aarti Singh, Danilo Faccenda & Michelangelo Campanella. (2021) Pharmacological advances in mitochondrial therapy. EBioMedicine 65, pages 103244.
Crossref
Crossref
Kristina Bardova, Jiri Funda, Radek Pohl, Tomas Cajka, Michal Hensler, Ondrej Kuda, Petra Janovska, Katerina Adamcova, Ilaria Irodenko, Lucie Lenkova, Petr Zouhar, Olga Horakova, Pavel Flachs, Martin Rossmeisl, Jerry Colca & Jan Kopecky. (2020) Additive Effects of Omega-3 Fatty Acids and Thiazolidinediones in Mice Fed a High-Fat Diet: Triacylglycerol/Fatty Acid Cycling in Adipose Tissue. Nutrients 12:12, pages 3737.
Crossref
Crossref
Kalina Duszka, András Gregor, Hervé Guillou, Jürgen König & Walter Wahli. (2020) Peroxisome Proliferator-Activated Receptors and Caloric Restriction—Common Pathways Affecting Metabolism, Health, and Longevity. Cells 9:7, pages 1708.
Crossref
Crossref
F. Anthony Romero, Christopher T. Jones, Yingzi Xu, Martijn Fenaux & Randall L. Halcomb. (2020) The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease. Journal of Medicinal Chemistry 63:10, pages 5031-5073.
Crossref
Crossref
Stephen A. Harrison, Naim Alkhouri, Beth A. Davison, Arun Sanyal, Christopher Edwards, Jerry R. Colca, Bo Hyun Lee, Rohit Loomba, Kenneth Cusi, Orville Kolterman, Gad Cotter & Howard C. Dittrich. (2020) Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study. Journal of Hepatology 72:4, pages 613-626.
Crossref
Crossref
Zita Wachal, Mariann Bombicz, Dániel Priksz, Csaba Hegedűs, Diána Kovács, Adrienn Mónika Szabó, Rita Kiss, József Németh, Béla Juhász, Zoltán Szilvássy & Balázs Varga. (2020) Retinoprotection by BGP-15, a Hydroximic Acid Derivative, in a Type II Diabetic Rat Model Compared to Glibenclamide, Metformin, and Pioglitazone. International Journal of Molecular Sciences 21:6, pages 2124.
Crossref
Crossref
Steven P. Tanis, Jerry R. Colca, Timothy T. Parker, Gerald D. ArtmanIIIIII, Scott D. Larsen, Robert C. Gadwood & James R. Zeller. (2019) The development of improved syntheses of PPARγ-sparing, insulin sensitizing thiazolidinedione-ketones. Tetrahedron Letters 60:33, pages 150931.
Crossref
Crossref
Alexandre Vallée, Yves Lecarpentier & Jean-Noël Vallée. (2019) Targeting the Canonical WNT/β-Catenin Pathway in Cancer Treatment Using Non-Steroidal Anti-Inflammatory Drugs. Cells 8:7, pages 726.
Crossref
Crossref
Sun-Young Kim, Ji-Young Jeon, Shin Jung Park & Min-Gul Kim. (2019) Pharmacokinetics of a Lobeglitazone/Metformin Fixed-Dose Combination Tablet (CKD-395 0.5/1000 mg) Versus Concomitant Administration of Single Agents and the Effect of Food on the Metabolism of CKD-395 in Healthy Male Subjects. Clinical Pharmacology in Drug Development 8:5, pages 576-584.
Crossref
Crossref
Sotiria Tavoulari, Chancievan Thangaratnarajah, Vasiliki Mavridou, Michael E Harbour, Jean‐Claude Martinou & Edmund RS Kunji. (2019) The yeast mitochondrial pyruvate carrier is a hetero‐dimer in its functional state. The EMBO Journal 38:10.
Crossref
Crossref
Andrew J. Krentz, Christian Weyer & Marcus Hompesch. 2019. Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease. Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease
3
35
.
Emmanuel Quansah, Wouter Peelaerts, J. William Langston, David K. Simon, Jerry Colca & Patrik Brundin. (2018) Targeting energy metabolism via the mitochondrial pyruvate carrier as a novel approach to attenuate neurodegeneration. Molecular Neurodegeneration 13:1.
Crossref
Crossref
Steven P. Tanis, Jerry R. Colca, Timothy T. Parker, Gerald D. ArtmanIIIIII, Scott D. Larsen, William G. McDonald, Robert C. Gadwood, Rolf F. Kletzien, James B. Zeller, Pil H. Lee & Wade J. Adams. (2018) PPARγ-sparing thiazolidinediones as insulin sensitizers. Design, synthesis and selection of compounds for clinical development. Bioorganic & Medicinal Chemistry 26:22, pages 5870-5884.
Crossref
Crossref
Fan Hong, Pengfei Xu & Yonggong Zhai. (2018) The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development. International Journal of Molecular Sciences 19:8, pages 2189.
Crossref
Crossref
Ting-Wei Lee, Kuan-Jen Bai, Ting-I Lee, Tze-Fan Chao, Yu-Hsun Kao & Yi-Jen Chen. (2017) PPARs modulate cardiac metabolism and mitochondrial function in diabetes. Journal of Biomedical Science 24:1.
Crossref
Crossref
Wan Leung, Feng-Ming Ho, Wen-Pin Li & Yu-Chih Liang. (2017) Vitis thunbergii var. taiwaniana Leaf Extract Reduces Blood Glucose Levels in Mice with Streptozotocin-induced Diabetes. International Journal of Pharmacology 13:5, pages 457-464.
Crossref
Crossref
Ana L. Perdigoto, Lawrence H. Young & Silvio E. Inzucchi. (2017) Pioglitazone and cardiovascular risk reduction: time for a second look?. Cardiovascular Endocrinology 6:2, pages 55-61.
Crossref
Crossref
Jerry R. Colca, William G. McDonald, Kyle S. McCommis & Brian N. Finck. (2017) Treating fatty liver disease by modulating mitochondrial pyruvate metabolism. Hepatology Communications 1:3, pages 193-197.
Crossref
Crossref
Indrajit Roy, Ridhima Juneja, Komal Sethi & Neeraj Vij. 2017. Drug Delivery. Drug Delivery
481
494
.
Andrew J. Krentz & Alan J. Sinclair. 2017. Diabetes in Old Age. Diabetes in Old Age
298
322
.
Yadan Chen, Haiming Ma, Dasheng Zhu, Guowei Zhao, Lili Wang, Xiujuan Fu & Wei Chen. (2017) Discovery of Novel Insulin Sensitizers: Promising Approaches and Targets. PPAR Research 2017, pages 1-13.
Crossref
Crossref
A. Ghosh, T. Tyson, S. George, E. N. Hildebrandt, J. A. Steiner, Z. Madaj, E. Schulz, E. Machiela, W. G. McDonald, M. L. Escobar Galvis, J. H. Kordower, J. M. Van Raamsdonk, J. R. Colca & P. Brundin. (2016) Mitochondrial pyruvate carrier regulates autophagy, inflammation, and neurodegeneration in experimental models of Parkinsons disease. Science Translational Medicine 8:368, pages 368ra174-368ra174.
Crossref
Crossref
Dražen Pavlović & Stjepan Mutak. (2016) Synthesis and antibacterial evaluation of novel 4″-glycyl linked quinolyl-azithromycins with potent activity against macrolide-resistant pathogens. Bioorganic & Medicinal Chemistry 24:6, pages 1255-1267.
Crossref
Crossref
Mingming Fang, Zhiwen Fan, Wenfang Tian, Yuhao Zhao, Ping Li, Huihui Xu, Bisheng Zhou, Liping Zhang, Xiaoyan Wu & Yong Xu. (2016) HDAC4 mediates IFN-γ induced disruption of energy expenditure-related gene expression by repressing SIRT1 transcription in skeletal muscle cells. Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms 1859:2, pages 294-305.
Crossref
Crossref
Kyle S. McCommis, Zhouji Chen, Xiaorong Fu, William G. McDonald, Jerry R. Colca, Rolf F. Kletzien, Shawn C. Burgess & Brian N. Finck. (2015) Loss of Mitochondrial Pyruvate Carrier 2 in the Liver Leads to Defects in Gluconeogenesis and Compensation via Pyruvate-Alanine Cycling. Cell Metabolism 22:4, pages 682-694.
Crossref
Crossref
Ralph A. DeFronzo, Ele Ferrannini, Leif Groop, Robert R. Henry, William H. Herman, Jens Juul Holst, Frank B. Hu, C. Ronald Kahn, Itamar Raz, Gerald I. Shulman, Donald C. Simonson, Marcia A. Testa & Ram Weiss. (2015) Type 2 diabetes mellitus. Nature Reviews Disease Primers 1:1.
Crossref
Crossref
Santiago Garcia-Vallvé, Laura Guasch, Sarah Tomas-Hernández, Josep Maria del Bas, Vincent Ollendorff, Lluís Arola, Gerard Pujadas & Miquel Mulero. (2015) Peroxisome Proliferator-Activated Receptor γ (PPARγ) and Ligand Choreography: Newcomers Take the Stage. Journal of Medicinal Chemistry 58:14, pages 5381-5394.
Crossref
Crossref
S.‐M. Jin, C.‐Y. Park, Y. M. Cho, B. J. Ku, C. W. Ahn, B.‐S. Cha, K. W. Min, Y. A. Sung, S. H. Baik, K. W. Lee, K.‐H. Yoon, M.‐K. Lee & S. W. Park. (2015)
Lobeglitazone and pioglitazone as add‐ons to metformin for patients with type 2 diabetes: a 24‐week, multicentre, randomized, double‐blind, parallel‐group, active‐controlled, phase
III
clinical trial with a 28‐week extension
. Diabetes, Obesity and Metabolism 17:6, pages 599-602.
Crossref
Crossref
Lingling Fan, Jianta Wang, Xiao Ma, Wan Xiao, Zhiyan Li, Gang Zhong, Lei Tang & Haoshu Wu. (2015) Design, synthesis and biological evaluation of GY3-based derivatives for anti-type 2 diabetes activity. Bioorganic & Medicinal Chemistry Letters 25:7, pages 1500-1505.
Crossref
Crossref
Andrew J. Krentz, Lutz Heinemann & Marcus Hompesch. 2015. Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development. Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development
3
43
.
J. R. Colca, W. G. McDonald & R. F. Kletzien. (2014) Mitochondrial target of thiazolidinediones. Diabetes, Obesity and Metabolism 16:11, pages 1048-1054.
Crossref
Crossref
Ralph A. DeFronzo, Curtis L. Triplitt, Muhammad Abdul-Ghani & Eugenio Cersosimo. (2014) Novel Agents for the Treatment of Type 2 Diabetes. Diabetes Spectrum 27:2, pages 100-112.
Crossref
Crossref